What is the prevalence of Homocystinuria?

TL;DR: Homocystinuria, specifically the most common form caused by cystathionine beta-synthase (CBS) deficiency, has an estimated worldwide incidence ranging from 1 in 100,000 to 1 in 300,000 live births. Because many cases are asymptomatic or misdiagnosed, the true global prevalence remains difficult to pinpoint, though it is definitively classified as a rare genetic metabolic disorder.

What is the estimated prevalence and incidence of Homocystinuria?

Estimating the exact number of people living with Homocystinuria is challenging due to the variability in clinical presentation and the impact of newborn screening programs. While global incidence is often cited between 1:100,000 and 1:300,000, these figures fluctuate significantly by region. For example, in Ireland, the incidence of Homocystinuria has been reported as high as 1 in 65,000 due to a founder effect. It is considered a rare disease globally, though it is a significant focus within metabolic medicine due to the severe potential complications if left untreated.

Does Homocystinuria affect specific genders or age groups differently?

Homocystinuria affects males and females with equal frequency, as it is typically inherited in an autosomal recessive pattern. Regarding age of onset, the condition is most commonly diagnosed during childhood following the emergence of symptoms such as intellectual disability, skeletal abnormalities (like Marfanoid habitus), or lens dislocation (ectopia lentis). However, "late-onset" or milder forms of Homocystinuria may not be diagnosed until adulthood, often presenting as premature thromboembolic events (blood clots). Because of this, clinicians must maintain a high index of suspicion for patients of all ages presenting with unexplained vascular issues.

Are there geographic or ethnic variations in the prevalence of Homocystinuria?

Yes, geographic and ethnic clusters are well-documented in the literature. While the classic form of Homocystinuria is rare in most populations, specific mutations are more prevalent in certain groups. In addition to the Irish population, higher carrier frequencies have been identified in specific cohorts in the Middle East and among certain European populations. These variations are primarily due to genetic isolation and founder effects within those specific communities.

Why is accurate data on Homocystinuria prevalence difficult to obtain?

The primary barrier to accurate data collection is the significant underdiagnosis of milder phenotypes. Factors contributing to the gap between estimated and actual prevalence include:

• Asymptomatic presentation: Some individuals with Homocystinuria have residual enzyme activity that prevents severe early-childhood symptoms.


• Diagnostic gaps: In regions without robust newborn screening programs, cases may be missed until a major medical event occurs in adolescence or adulthood.


• Misdiagnosis: Symptoms can overlap with other connective tissue disorders, leading to diagnostic overshadowing.


• Community perspective: At DiseaseMaps.org, we currently have 38 community members who have shared their experiences with Homocystinuria. This real-world data helps researchers understand the patient journey beyond clinical statistics, highlighting the importance of patient registries in tracking rare disease trends.

Next steps

• Consult with a metabolic specialist or geneticist if you have a family history or clinical suspicion of Homocystinuria.


• Request a referral for biochemical testing (plasma amino acids) to check for elevated homocysteine levels.


• Connect with the DiseaseMaps.org community to share your journey and learn from others living with the condition.


• Review the latest clinical trial information via NIH ClinicalTrials.gov to see if you or a family member are eligible for emerging research.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of a qualified healthcare provider with any questions regarding a medical condition.

References

• Orphanet: Homocystinuria due to cystathionine beta-synthase deficiency (ORPHA:408).


• NIH Genetic and Rare Diseases Information Center (GARD): Homocystinuria.


• OMIM (Online Mendelian Inheritance in Man): Cystathionine Beta-Synthase Deficiency (Entry #236200).


• Journal of Inherited Metabolic Disease: Global perspectives on the epidemiology of inherited metabolic disorders.